Literature DB >> 17921035

Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek.

Anne M Wallace1, Carl K Hoh, Denise D Darrah, Gery Schulteis, David R Vera.   

Abstract

Lymphoseek is a molecular imaging agent specifically designed for sentinel lymph node (SLN) mapping. We conducted a Phase I trial which measured the injection site clearance and SLN accumulation after a single intra dermal injection of Lymphoseek or [99mTc]sulfur colloid protocol. Ten patients with breast cancer participated in this study. Five patients received an intradermal administration of 1.0 nmol of 99mTc-labeled Lymphoseek and five patients received an intradermal administration of filtered [99mTc]sulfur colloid (fTcSC). Lymphoseek exhibited a significantly (P<.001) faster injection site clearance than fTcSC. The mean Lymphoseek clearance half-time was 2.61+/-0.72 h compared to 24.1+/-17.7 h for fTcSC. The mean SLN uptake of Lymphoseek (1.1+/-.5%) and fTcSC (2.5+/-4.9%) was statistically equivalent (P=.28). When an intra dermal injection was employed, Lymphoseek demonstrated faster injection site clearance than fTcSC.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17921035      PMCID： PMC4189800          DOI： 10.1016/j.nucmedbio.2007.05.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  13 in total

1.  Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients.

Authors:  D C Linehan; A D Hill; T Akhurst; H Yeung; S D Yeh; K N Tran; P I Borgen; H S Cody
Journal:  Ann Surg Oncol       Date:  1999 Jul-Aug       Impact factor: 5.344

2.  Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols.

Authors:  H W Yeung; H S Cody III; A Turlakow; E R Riedel; J Fey; M Gonen; R Nuñez; S D Yeh; S M Larson
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

3.  Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study.

Authors:  K M McMasters; S L Wong; R C Martin; C Chao; T M Tuttle; R D Noyes; D J Carlson; A L Laidley; T Q McGlothin; P B Ley; C M Brown; R L Glaser; R E Pennington; P S Turk; D Simpson; P B Cerrito; M J Edwards
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

4.  Minimally invasive sentinel lymph node mapping of the pig colon with Lymphoseek.

Authors:  Anne M Wallace; Scott J Ellner; Jeanette Méndez; Carl K Hoh; Carol E Salem; Carl M Bosch; Richard C Orahood; David R Vera
Journal:  Surgery       Date:  2006-02       Impact factor: 3.982

5.  A preclinical study of prostate sentinel lymph node mapping with [99mTC]diethylenetetramine pentaacetic acid-mannosyl-dextran.

Authors:  Carol E Salem; Carl K Hoh; Anne M Wallace; David R Vera
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

6.  Preclinical studies of [(99m)Tc]DTPA-mannosyl-dextran .

Authors:  Carl K Hoh; Anne M Wallace; David R Vera
Journal:  Nucl Med Biol       Date:  2003-07       Impact factor: 2.408

7.  Sentinel lymph node mapping of the colon and stomach using lymphoseek in a pig model.

Authors:  Scott J Ellner; Jeanette Méndez; David R Vera; Carl K Hoh; William L Ashburn; Anne M Wallace
Journal:  Ann Surg Oncol       Date:  2004-07       Impact factor: 5.344

8.  Detection of gastric and colonic sentinel nodes through endoscopic administration of 99mTc-DTPA-mannosyl-dextran in pigs.

Authors:  Jeanette Méndez; Anne M Wallace; Carl K Hoh; David R Vera
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

9.  Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping.

Authors:  Scott J Ellner; Carl K Hoh; David R Vera; Denise D Darrah; Gery Schulteis; Anne M Wallace
Journal:  Nucl Med Biol       Date:  2003-11       Impact factor: 2.408

10.  Lymphoseek: a molecular radiopharmaceutical for sentinel node detection.

Authors:  Anne M Wallace; Carl K Hoh; David R Vera; Denise D Darrah; Gery Schulteis
Journal:  Ann Surg Oncol       Date:  2003-06       Impact factor: 5.344
View more
  13 in total

Review 1.  The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.

Authors:  Christopher A Tokin; Frederick O Cope; Wendy L Metz; Michael S Blue; Beth M Potter; Bonnie C Abbruzzese; Richard D Hartman; Marcus T Joy; Dennis W King; Lori A Christman; David R Vera; Anne M Wallace
Journal:  Clin Exp Metastasis       Date:  2012-06-23       Impact factor: 5.150

Review 2.  The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Authors:  Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath
Journal:  Nucl Med Biol       Date:  2015-12-03       Impact factor: 2.408

Review 3.  Oral cavity squamous cell carcinoma and the clinically n0 neck: the past, present, and future of sentinel lymph node biopsy.

Authors:  Andrew Coughlin; Vicente A Resto
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

Review 4.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

5.  A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.

Authors:  Stanley P L Leong; Julian Kim; Merrick Ross; Mark Faries; Charles R Scoggins; Wendy L Rich Metz; Frederick O Cope; Richard C Orahood
Journal:  Ann Surg Oncol       Date:  2011-02-18       Impact factor: 5.344

6.  Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol.

Authors:  Anne M Wallace; Carl K Hoh; Karl K Limmer; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

7.  Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.

Authors:  Vernon K Sondak; Dennis W King; Jonathan S Zager; Schlomo Schneebaum; Julian Kim; Stanley P L Leong; Mark B Faries; Bruce J Averbook; Steve R Martinez; Christopher A Puleo; Jane L Messina; Lori Christman; Anne M Wallace
Journal:  Ann Surg Oncol       Date:  2012-10-03       Impact factor: 5.344

Review 8.  Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection.

Authors:  Christoph Tausch; Astrid Baege; Christoph Rageth
Journal:  Onco Targets Ther       Date:  2014-06-24       Impact factor: 4.147

9.  Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients.

Authors:  Jennifer L Baker; Minya Pu; Christopher A Tokin; Carl K Hoh; David R Vera; Karen Messer; Anne M Wallace
Journal:  Ann Surg Oncol       Date:  2014-07-29       Impact factor: 5.344

10.  Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.

Authors:  Anne M Wallace; Linda K Han; Stephen P Povoski; Kenneth Deck; Schlomo Schneebaum; Nathan C Hall; Carl K Hoh; Karl K Limmer; Helen Krontiras; Thomas G Frazier; Charles Cox; Eli Avisar; Mark Faries; Dennis W King; Lori Christman; David R Vera
Journal:  Ann Surg Oncol       Date:  2013-03-17       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.